Crystal forms of GLP-1R agonists and uses thereof
Crystalline forms of Compound (A) represented by the following structural formula, and their corresponding pharmaceutical compositions, are disclosed. The crystalline forms are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating or preventing diseases or conditions such as type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease in a subject.
1 . A crystalline Form I of Compound A,
characterized by an X-ray powder diffraction (XRPD) pattern which comprises peaks selected from 11.4°, 12.7°, 18.1°, and 18.3°±0.2 in 2θ.
2 . The crystalline Form I of claim 1 , wherein the X-ray powder diffraction pattern further comprises one or more peaks at 4.9°, 11.8°, and 21.5°±0.2 in 2θ.
3 . The crystalline Form I of claim 2 , wherein the X-ray powder diffraction pattern further comprises one or more peaks at 15.8°, 18.8°, and 23.0°±0.2 in 2θ.
4 . The crystalline Form I of claim 1 , wherein the X-ray powder diffraction pattern comprises peaks at 4.9°, 11.4°, 11.8°, 12.7°, 15.8°, 18.1°, 18.3°, 18.8°, 21.5°, and 23.0°±0.2 in 2θ.
5 . The crystalline Form I of claim 1 , characterized by a differential scanning calorimeter (DSC) peak phase transition temperature of 200±3° C.
6 . The crystalline Form I of claim 1 , wherein at least 90% by weight of the Compound A is crystalline Form I.
7 . A crystalline Form II of Compound A,
characterized by an X-ray powder diffraction pattern which comprises peaks selected from 11.4°, 12.0°, 12.9°, 18.6°, and 20.4°±0.2 in 2θ.
8 . The crystalline Form II of claim 7 , wherein the X-ray powder diffraction pattern does not comprise peaks at 18.1° and/or 21.5°±0.2 in 2θ.
9 . The crystalline Form II of claim 8 , wherein the X-ray powder diffraction pattern further comprises one or more peaks at 4.9°, 7.7°, 15.8°, and 25.9°±0.2 in 2θ.
10 . The crystalline Form II of claim 7 , characterized by an X-ray powder diffraction pattern which comprises peaks at 4.9°, 7.7°, 11.4°, 12.0°, 12.9°, 15.8°, 18.6°, 20.4°, and 25.9°±0.2 in 2θ.
11 . The crystalline Form II of claim 7 , characterized by a differential scanning calorimeter (DSC) peak phase transition temperature of 205±3° C.
12 . The crystalline Form II of claim 7 , wherein at least 90% by weight of the Compound A is crystalline Form II.
13 . A crystalline Form III of Compound A,
characterized by an X-ray powder diffraction pattern which comprises peaks selected from 9.8°, 13.3°, 17.3°, and 18.1°±0.2 in 2θ.
14 . The crystalline Form III of claim 13 , wherein the X-ray powder diffraction pattern further comprises one or more peaks at 11.7°, 14.2°, 24.7°, 26.3 and 27.7°±0.2 in 2θ.
15 . The crystalline Form III of claim 13 , wherein the crystalline Form III is characterized by an X-ray powder diffraction pattern which comprises peaks at 9.8°, 11.7°, 13.3°, 14.2°, 17.3°, 18.1°, 24.7°, 26.3°, and 27.7°±0.2 in 2θ.
16 . The crystalline Form III of claim 13 , characterized by a differential scanning calorimeter (DSC) peak phase transition temperature of 204±3° C.
17 . The crystalline Form III of claim 13 , wherein the crystalline Form III is hydrate.
18 . The crystalline Form III of claim 13 , wherein at least 90% by weight of the Compound A is crystalline Form III.
19 . A pharmaceutical composition comprising a crystalline form of Compound A of claim 1 , and a pharmaceutically acceptable carrier.
20 . A method of treating or preventing a disease or condition, the method comprising administering to a subject in need of treatment a therapeutically effective amount of a crystalline form of Compound A of claim 1 , or a pharmaceutical composition thereof, wherein the disease or condition is T1D, T2DM, pre-diabetes, idiopathic T1D, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea, obesity, eating disorders, weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, cirrhosis, hepatocellular carcinoma, cardiovascular disease, atherosclerosis, coronary artery disease, peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson's Disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer's Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome Crohn's disease, colitis, irritable bowel syndrome, Polycystic Ovary Syndrome, or addiction.